ライフサイエンスコーパス: bradykinin B2 receptor

1 h either epidermal growth factor receptor or bradykinin B2 receptor.

2 prototypical G protein-coupled receptor, the bradykinin B2 receptor.

3 tory interactions with the G protein-coupled bradykinin B2 receptor.

4 hose with caveolin-1 but also occur with the bradykinin B2 receptor.

5 2 nM as cells transfected with the wild type bradykinin B2 receptor.

6 n of bradykinin and subsequent activation of bradykinin B2 receptors.

7 iggered by activation of adenosine A1/A3 and bradykinin B2 receptors.

8 (I(M)) suppression by muscarinic M1, but not bradykinin B2, receptors.

9 inhibitors are partly mediated by increased bradykinin B2 receptor activation, this study aimed to d

10 g effects of bradykinin are mediated through bradykinin B2 receptors, and that differences in distrib

11 olished by pretreatment of the animal with a bradykinin B2 receptor antagonist (HOE 140).

12 e Pro2-Pro3-Gly4-Phe5 section of the peptide bradykinin B2 receptor antagonist [Pro3, Phe5]HOE 140 (D

13 methacin, l-NG-nitroarginine methyl ester, a bradykinin B2 receptor antagonist and tetrodotoxin.

14 in December 2009) and icatibant (a selective bradykinin B2 receptor antagonist approved for use in th

15 a kallikrein inhibitor sebetralstat and oral bradykinin B2 receptor antagonist deucrictibant.

16 adykinin (1 microM) and was abolished by the bradykinin B2 receptor antagonist HOE 140 (1 microM).

17 The bradykinin B2 receptor antagonist HOE 140 abolished the

18 ty response to bradykinin was blocked by the bradykinin B2 receptor antagonist HOE 140, by inhibition

19 hibitor l-N(6)-nitroarginine methyl ester or bradykinin B2 receptor antagonist icatibant.

20 tudy does not support clinical efficacy of a bradykinin B2 receptor antagonist in ACE inhibitor-assoc

21 We sought to test the hypothesis that a bradykinin B2 receptor antagonist would shorten time-to-

22 in tumors was significantly inhibited by the bradykinin B2 receptor antagonist, d-Arg, [Hyp3, Thi5,8,

23 Icatibant, a bradykinin B2 receptor antagonist, is an established tre

24 30 mg of subcutaneous icatibant, a selective bradykinin B2 receptor antagonist, or to the current off

25 Hoe 140, a bradykinin B2-receptor antagonist, had no effect on the

26 ted rats was abolished by application of the bradykinin B2-receptor antagonist, icatibant (0.5 mg/kg)

27 dykinin with HOE-140 (0.3 mg/kg), a specific bradykinin B2-receptor antagonist, produced no significa

28 Both bradykinin B2 receptor antagonists had no significant ef

29 ted by NPC 17647 and Hoe 140 (p < 0.05), two bradykinin B2 receptor antagonists, but not by desArg9,[

30 We conclude that bradykinin B2 receptors are expressed in skeletal muscle

31 differential dynamic regulation of endosomal bradykinin B2 receptor (B2R) complexes with either beta-

32 targeting of the C5a receptor (C5aR) or the bradykinin B2 receptor (B2R) inhibited plasma leakage in

33 TAp73 also activated the bradykinin B2 receptor (B2R) promoter, a developmentally

34 led receptor (GPCR) mRNAs, including that of bradykinin B2 receptor (B2R).

35 Bradykinin-B2-receptor (B2R) blockade by icatibant subst

36 llular loop (IC1) in the function of the rat bradykinin B2 receptor (BKB2R) was probed.

37 ein, high-molecular-weight kininogen, or the bradykinin B2 receptor, but not the B1 receptor, largely

38 bioavailable, competitive antagonist of the bradykinin B2 receptor currently under investigation for

39 Bradykinin B2 receptor-deleted mice (Bdkrb2(-/-)) have d

40 ated terminals of dental pulp fibers via the bradykinin B2 receptor-dependent mechanism.

41 trating that Akita diabetic mice lacking the bradykinin B2 receptor develop overt albuminuria, excret

42 late Ras, we examined whether PDGF regulates bradykinin B2 receptor expression in cultured arterial s

43 e icatibant, a competitive antagonist of the bradykinin B2 receptors, for the treatment of inpatients

44 It was demonstrated that the bradykinin B2 receptor gene (BdkrB2) is a direct transcr

45 and P2 may be important in the regulation of bradykinin B2 receptor gene expression in response to in

46 protein revealed that virtually 100% of the bradykinin B2 receptor-immunoreactive positive cells wer

47 The widespread distribution of bradykinin B2 receptor immunoreactivity in neuronal comp

48 or to establish the cellular distribution of bradykinin B2 receptor immunoreactivity in the rat brain

49 Bradykinin B2 receptor immunoreactivity was also present

50 Bradykinin B2 receptor immunoreactivity was ubiquitously

51 tumor permeability specifically involves the bradykinin B2 receptor in brain tumor tissue.

52 Activation of the bradykinin B2 receptor in endothelial cells initiates a

53 -converting enzyme levels, or absence of the bradykinin B2 receptor, increase kidney damage in diabet

54 Thus, absence of the bradykinin B2 receptor increases the oxidative stress, m

55 In a recent study, both a bradykinin B2 receptor inhibitor (icatibant acetate) and

56 ental studies suggest that activation of the bradykinin B2 receptor is an important trigger of ischem

57 of the amino acid motif(s) participating in bradykinin B2 receptor-mediated signal transduction proc

58 These data suggest that a strong bradykinin B2-receptor-mediated upregulation of osteopon

59 ever, chronic ACE inhibition caused a marked bradykinin/B2 receptor-mediated increase in LV ISF chyma

60 rast to S1P, activation of G protein-coupled bradykinin B2 receptors neither activates kinase Akt nor

61 By contrast, expression of neither bradykinin B2 receptors nor the scaffolding protein cave

62 stimulation of diverse receptors, including bradykinin B2 receptors on endothelial cells.

63 n of Gq protein-coupled thromboxane A(2) and bradykinin B2 receptors on muscle afferent sensory endin

64 coupled receptors (e.g. thromboxane A(2) and bradykinin B2 receptors) on the sensory endings of thin

65 ion of NHE-1 is blocked by inhibitors of the bradykinin B2 receptor, phospholipase C, Ca2+/calmodulin

66 These data demonstrate that the bradykinin B2 receptor physically associates with eNOS i

67 tions -70 and -707, respectively, in the rat bradykinin B2 receptor promoter.

68 using a scanning format, we have chosen the bradykinin B2 receptor system in the NG108-15 cell line,

69 -acid portion of the C-terminal of the human bradykinin B2 receptor to establish the cellular distrib

70 pendent depolarization through activation of bradykinin B2 receptors, to which eNOS is physically com

71 internalization, and resensitization of the bradykinin B2 receptor, we identified two critical motif

72 Rat-1 cells, which do not contain detectable bradykinin B2 receptor, were transfected with wild type

73 Double-labeling experiments colocalizing the bradykinin B2 receptor with the neuronal marker NeuN or